WEKO3
アイテム
In vivo tau PET imaging using [11C]PBB3 in patients with PSP and CBS
https://repo.qst.go.jp/records/71630
https://repo.qst.go.jp/records/71630e0ca9817-520b-4b3a-a98a-f09504e98c2b
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2015-04-20 | |||||
| タイトル | ||||||
| タイトル | In vivo tau PET imaging using [11C]PBB3 in patients with PSP and CBS | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Shimada, Hitoshi
× Shimada, Hitoshi× Hirano, Shigeki× Shinotoh, Hitoshi× Furukawa, Shogo× Eguchi, Yoko× Takahata, Keisuke× Kimura, Yasuyuki× Ikoma, Youko× Yamada, Makiko× Zhang, Ming-Rong× Ito, Hiroshi× Higuchi, Makoto× Kuwabara, Satoshi× Suhara, Tetsuya× 島田 斉× 平野 成樹× 篠遠 仁× 古川 彰吾× 江口 洋子× 高畑 圭輔× 木村 泰之× 生駒 洋子× 山田 真希子× 張 明栄× 伊藤 浩× 樋口 真人× 須原 哲也 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Objective: To investigate characteristics of [11C]PBB3 binding and its relation with clinical aspects in patients with progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Background: [11C]PBB3 is a novel tau imaging positron emission tomography (PET) ligand, which could visualize the tau deposition in Alzheimer’s disease (AD) and non-AD tauopathies such as PSP, CBS and frontotemporal dementia. Methods: Participants included 10 PSP patients, 9 patients with corticobasal syndrome (CBS), 19 AD patients, and 20 age and gender matched healthy controls (HCs). A dose (about 10 mCi) of [11C]PBB3 was intravenously injected and sequential PET scans were performed for 70 min. We also performed PET scan with a plaque-binding agent, [11C]PIB (about 10 mCi), for 70 min and threedimensional T1-weighted MRI. Standardized uptake value ratio (SUVR) was calculated for each PET image using the cerebellar cortex as reference region. Amyloid deposition was verified by visual assessment of SUVR images of [11C]PIB PET. As for [11C]PBB3 PET data, group analysis among each group was performed by oneway ANOVA using statistical parametric mapping software (spm5). Results: One CBS patient and 17 of 19 AD patients were PIBpositive, and all the rest participants were PIB-negative. One PIBpositive CBS and two PIB-negative AD patients were excluded from group analysis. [11C]PBB3 was accumulated in lesions associated with neurological symptoms in PSP, CBS and AD patients. To be specific, [11C]PBB3 binding was significantly increased in the brainstem, basal ganglia, thalamus and dentate nucleus in PSP patients compared to HCs. In PIB-negative CBS patients, remarkable uptake of [11C]PBB3 was observed in basal ganglia and the neocortex including the supplementary motor area (SMA) and the peri-Rolandic area compared to HCs. Furthermore, [11C]PBB3 retention observed in PIB-positive CBS patient extended the neocortex as well as the entire limbic system, resembling AD patients with profound cognitive decline. Some brain lesions with [11C]PBB3 binding exhibited brain atrophy in PSP, CBS and AD patients. Conclusions: The present study demonstrated that distribution patterns of [11C]PBB3 binding reflect the differences in tau distribution in PSP, CBS and AD patients, which are highly compatible with neurological manifestation in each disorder. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第18回国際パーキンソン病・運動障害疾患会議（MDS2014） | |||||
| 発表年月日 | ||||||
| 日付 | 2014-06-09 | |||||
| 日付タイプ | Issued | |||||
